Formulation and In Vitro Evaluation of Self Microemulsifying Drug Delivery System Containing Atorvastatin Calcium

Author:

Diril Mine1,Türkyılmaz Gülbeyaz Yıldız1,Karasulu H. Yeşim1

Affiliation:

1. Department of Pharmaceutical Technology, Faculty of Pharmacy, Ege University, Izmir, Turkey

Abstract

Objective: The aim of this study was to develop a new dosage form as an alternative to the classical tablet forms of atorvastatin calcium (AtrCa). The formulation strategy was to prepare an optimum self micro emulsifying drug delivery system (SMEDDS) to overcome the problem of low solubility of the active substance. Methods: In this study, pseudo ternary phase diagrams were plotted determined by the solubility studies. According to the solubility studies; oleic acid was used as the oil phase, Tween 20 and Span 80 were used as the surfactants and ethanol was used as the co-surfactant. SMEDDS formulations were characterized according to pH, electrical conductivity, density, refractive index, viscosity, emulsification time, dispersibility, robustness of dilution stability, droplet size, polidispersity index, zeta potential, transmittance %, cloud point, content quantification %, chemical and physical stability. The lipolysis study was conducted under fed and fasted conditions. In vitro release studies and kinetic evaluation were carried out. Permeability studies were also examined with Caco-2 cell culture. Results: The droplet size of the optimized formulation did not change significantly in different medias over the test time period. Improved SMEDDS formulation will progress steadily without precipitating along the gastrointestinal tract. Lipolysis studies showed that the oil solution had been exposed to high amount of lipolysis compared to the SMEDDS formulation. The release rate of AtrCa from AtrCa- SMEDDS formulation (93.8%, at 15 minutes) was found as increased when the results were compared with commercial tablet formulation and pure drug. The permeability value of AtrCa from AtrCa- SMEDDS formulation was found higher than pure AtrCa and commercial tablet formulation, approximately 9.94 and 1.64 times, respectively. Conclusion: Thus, lipid-based SMEDDS formulation is a potential formulation candidate for lymphatic route in terms of the increased solubility of AtrCa.

Funder

Ege University

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmaceutical Science

Reference43 articles.

1. Frohlich E.D.; Quinlan P.J.; Coronary heart disease risk factors: Public impact of initial and later-announced risks. Ochsner J 2014,14(4),532-537

2. Defesche J.C.; Gidding S.S.; Harada-Shiba M.; Hegele R.A.; Santos R.D.; Wierzbicki A.S.; Familial hypercholesterolaemia. Nat Rev Dis Primers 2017,3(February),17093

3. Chong P.H.; Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors. Ann Pharmacother 2002,36(12),1907-1917

4. Mciver L.A.; Siddique M.S.; Atorvastatin., 2019, 1-4.

5. Center For Drug Evaluation And Research “Lipitor” U.S. Food and Drug Administration (FDA)2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3